Renaissance Capital logo

Structure Therapeutics Priced, Nasdaq: GPCR

Phase 1 biotech developing G-protein-coupled receptors for chronic diseases.

Industry: Health Care

Latest Trade: $40.84 -2.84 (-6.5%)

First Day Return: +73.3%

Return from IPO: +191.2%

Industry: Health Care

We are a clinical stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Our initial focus is on G-protein-coupled receptors, or GPCRs, as a therapeutic target class. We are developing GSBR-1290, our oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor, or GLP-1R, for the treatment of type-2 diabetes mellitus, or T2DM, and obesity. We completed our Phase 1 single ascending dose, or SAD, study of GSBR-1290 in September 2022. GSBR-1290 was generally well tolerated and demonstrated dose-dependent pharmacokinetics, or PK, and pharmacological, or PD, activity. We submitted an Investigational New Drug application, or IND, to the United States Food and Drug Administration, or FDA, to support initiation of a Phase 1b proof-of-concept study in T2DM and obesity and received FDA allowance in September 2022. We initiated the Phase 1b multiple ascending dose, or MAD, study in January 2023 and plan to submit a protocol amendment to the FDA to transition to a Phase 2a proof-of-concept study in T2DM and obesity with expected initiation in the second half of 2023. We expect to report topline data for the Phase 1b study and Phase 2a study in the second half of 2023.
more less
IPO Data
IPO File Date 01/12/2023
Offer Price $15.00
Price Range $13.00 - $15.00
Offer Shares (mm) 10.7
Deal Size ($mm) $161
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 02/02/2023
Offer Price $15.00
Price Range $13.00 - $15.00
Offer Shares (mm) 10.7
Deal Size ($mm) $161
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Jefferies
Leerink Partners
more
Company Data
Headquarters South San Francisco, CA, United States
Founded 2016
Employees 68
Website www.structuretx.com

Structure Therapeutics (GPCR) Performance